Back to news

MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain

Globe Newswire•17/11/2026•08:00 ET
0

Key Highlights

  • ➤MIRA-55 showed approximately 680-fold separation from mu opioid receptors.
  • ➤MIRA-55 showed 540-fold separation from kappa opioid receptors.
  • ➤MIRA-55 showed no substantial COX-1 or COX-2 inhibition at tested concentrations.
  • ➤MIRA targets an IND submission for MIRA-55 in the first half of 2027.
  • ➤Oral MIRA-55 reportedly outperformed injected morphine in an acute inflammatory pain model.

Expert Statements

Itzchak Angel, CSA of MIRA

“What makes MIRA-55 particularly compelling is the possibility of addressing pain through complementary biological pathways.”

Itzchak Angel, CSA of MIRA

“Our findings suggest a pharmacological profile that may influence both the inflammatory processes that contribute to pain and how pain signals are processed in the nervous system.”

Itzchak Angel, CSA of MIRA

“The combination of brain penetration, distinct receptor signaling, a broad receptor selectivity profile, and encouraging preclinical efficacy without significant THC-like motor impairment gives us a strong scientific rationale for believing MIRA-55 could represent a differentiated approach to pain treatment.”

Erez Aminov, CEO of MIRA

“We're building a differentiated pain franchise focused on significant unmet medical needs.”

Erez Aminov, CEO of MIRA

“MIRA-55 is designed to address inflammatory pain, while Ketamir-2 targets neuropathic pain and is advancing toward Phase 2 proof of concept in chemotherapy-induced peripheral neuropathy.”

Erez Aminov, CEO of MIRA

“Our strategy is to translate encouraging science into clinical evidence that can support meaningful treatment options for patients and create long-term value through future strategic partnerships.”

New Findings Highlight MIRA-55's Potent CB2 Activation With More Than 500-Fold Separation From Measured Mu, Delta, and Kappa Opioid Receptor Interactions

MIRA-55's Differentiated Profile Combines CB2/CB1 Activity, Brain Penetration, and Distinct Signaling With Encouraging Preclinical Pain Relief, Reduced Inflammation, and Anxiolytic-Like Effects Without Significant THC-Like Motor Impairment

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in